Volume 26, Issue 3 (Jun 2018)
JSSU 2018, 26(3): 275-285 |
Back to browse issues page
Fatemeh Barzegari firouzabadi 
, Shahrbanoo Oryan * , Mohammad Hasan Sheikhha , Seyed Mehdi Kalantar , Ameneh Javed
, Shahrbanoo Oryan * , Mohammad Hasan Sheikhha , Seyed Mehdi Kalantar , Ameneh Javed
Abstract: (2896 Views)
Introdution: The aim of this study was to investigate the physico-chemical properties, surface charge and cytotoxicity of nanocomposite formulations for the design of lipid nano-systems with maximum loading for nucleic acids in bone marrow cancer.
Methods For this study, six types of liposomes with different compositions were synthesized using DPPC, cholesterol, DSPE-mPEG (2000) and DOTAP. Then, nanosystems were evaluated for particle size, surface charge, cytotoxicity and loading rate of miRNA in two MG-63 and SaOs2 cell lines, which are human cell bone marrow cell lines.
Results: All nano-systems were monodisperse. Among the systems, the F6 formula has the lowest toxicity and the highest load of miRNA-143, due to the presence of a suitable amount of DOTAP and PEG phospholipid in the liposome structure.
Conclusion: Liposomal formulation with a suitable percentage of DOTAP cationic phospholipid can be used as a successful carrier for the transport of miRNA in the gene therapy process for the treatment of various cancers, especially metastatic types.
Methods For this study, six types of liposomes with different compositions were synthesized using DPPC, cholesterol, DSPE-mPEG (2000) and DOTAP. Then, nanosystems were evaluated for particle size, surface charge, cytotoxicity and loading rate of miRNA in two MG-63 and SaOs2 cell lines, which are human cell bone marrow cell lines.
Results: All nano-systems were monodisperse. Among the systems, the F6 formula has the lowest toxicity and the highest load of miRNA-143, due to the presence of a suitable amount of DOTAP and PEG phospholipid in the liposome structure.
Conclusion: Liposomal formulation with a suitable percentage of DOTAP cationic phospholipid can be used as a successful carrier for the transport of miRNA in the gene therapy process for the treatment of various cancers, especially metastatic types.
Type of Study: Original article |
Subject:
Biology
Received: 2018/01/13 | Accepted: 2018/02/10 | Published: 2018/08/19
Received: 2018/01/13 | Accepted: 2018/02/10 | Published: 2018/08/19
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |